19 results
CORRESP
ARAV
Aravive Inc
10 May 23
Correspondence with SEC
12:00am
: 1) license to intellectual property, Batiraxcept, and 2) research and development services (“R&D” services), including conducting clinical trials … is generally being evaluated for efficacy is typically indicative that the R&D activities are capable of being distinct as the customer can obtain R&D activities
8-K
EX-10.1
ARAV
Aravive Inc
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
).
8.2Prepaid R&D Payment. Within fifteen (15) Business Days after the Effective Date, 3D Medicines shall pay to Aravive a one-time, non-refundable, non
8-K
EX-99.1
xokjcsotiqpt ni6ioic
8 May 19
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:15pm
8-K
EX-99.1
qisw67x2xrrn6m13x
7 Mar 19
Results of Operations and Financial Condition
4:16pm
8-K
EX-99.1
uuaa88f d1
5 Feb 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
fg036uk vh0iz66w7xw
11 Dec 18
Other Events
9:00am
8-K
EX-99.1
fqrn 8hml
13 Nov 18
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
7:10am
8-K
EX-99.1
41oz9wj4zvgw8y5
6 Nov 18
Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
4:20pm
8-K/A
EX-99.1
qwlri9ae9a9plct97
8 Aug 18
Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments
4:09pm
425
EX-99.1
pdxmvms3a6kr
8 Aug 18
Business combination disclosure
4:07pm
8-K
EX-99.1
rxmum2ji xqu
7 Aug 18
Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments
12:00am
425
nraut6fgak
10 Jul 18
Business combination disclosure
4:28pm
8-K
EX-99.1
mc63 nymqiv
8 May 18
Versartis Reports First Quarter 2018 Financial Results
12:00am
8-K
EX-99.1
8fuld
5 Aug 14
Versartis Reports Second Quarter 2014 Financial Results
12:00am
- Prev
- 1
- Next